Cover Image
市場調查報告書

重積癲癇:開發平台分析

Status Epilepticus - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200492
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
重積癲癇:開發平台分析 Status Epilepticus - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 65 Pages
簡介

重積癲癇(SE)是指持續發作半小時以上,發作間意識無法回復的狀態。症狀有局部或半身知覺異常或無知覺,以視力低落或色彩豐富的幻覺為特徵的焦點視覺變化、幻嗅及幻味、不規則的腹部刺激等。

本報告提供重積癲癇的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

重積癲癇 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Ligand Pharmaceuticals, Inc.
  • Sage Therapeutics

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ADD-405008
  • fosphenytoin sodium
  • SAGE-217
  • SAGE-547
  • SAGE-689
  • SGE-102
  • Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus
  • TG-4155

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8261IDB

Summary

Global Markets Direct's, 'Status Epilepticus - Pipeline Review, H2 2016', provides an overview of the Status Epilepticus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Status Epilepticus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Status Epilepticus and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Status Epilepticus
  • The report reviews pipeline therapeutics for Status Epilepticus by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Status Epilepticus therapeutics and enlists all their major and minor projects
  • The report assesses Status Epilepticus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Status Epilepticus

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Status Epilepticus
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Status Epilepticus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Status Epilepticus Overview
  • Therapeutics Development
    • Pipeline Products for Status Epilepticus - Overview
    • Pipeline Products for Status Epilepticus - Comparative Analysis
  • Status Epilepticus - Therapeutics under Development by Companies
  • Status Epilepticus - Therapeutics under Investigation by Universities/Institutes
  • Status Epilepticus - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Status Epilepticus - Products under Development by Companies
  • Status Epilepticus - Products under Investigation by Universities/Institutes
  • Status Epilepticus - Companies Involved in Therapeutics Development
    • Marinus Pharmaceuticals, Inc.
    • Sage Therapeutics, Inc.
    • Shire Plc
  • Status Epilepticus - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AMPX-0079 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosphenytoin sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ganaxolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LSPGR-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • midazolam hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAGE-217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAGE-689 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sepranolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-4155 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Status Epilepticus - Dormant Projects
  • Status Epilepticus - Product Development Milestones
    • Featured News & Press Releases
      • Jun 22, 2016: Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV
      • Jun 13, 2016: Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures
      • Apr 19, 2016: Marinus Pharmaceuticals Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus
      • Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting
      • Apr 15, 2016: Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus
      • Apr 12, 2016: Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting
      • Mar 03, 2016: Sage Therapeutics to Present SAGE-547 Clinical Data and SRSE Health Economic Data in Five Abstracts at the American Academy of Neurology 2016 Annual Meeting
      • Dec 15, 2015: SAGE Updates Guidance for Top-Line Results of Phase 3 STATUS Trial of SAGE-547
      • Dec 02, 2015: SAGE to Present Poster Presentations on SAGE-547 at the American Epilepsy Society 69th Annual Meeting
      • Aug 17, 2015: SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus
      • Aug 06, 2015: SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus
      • Jun 09, 2015: SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression
      • May 14, 2015: SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus
      • Apr 22, 2015: Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
      • Apr 20, 2015: SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Status Epilepticus, H2 2016
  • Number of Products under Development for Status Epilepticus - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Status Epilepticus - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
  • Status Epilepticus - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Status Epilepticus - Pipeline by Shire Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Status Epilepticus - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Status Epilepticus, H2 2016
  • Number of Products under Development for Status Epilepticus - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top